Medical Information Notice: This article is for general education only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified clinician for your personal situation.

Bone cancer refers to malignant tumors originating in bone tissue (primary bone cancer) or cancers that spread to bones from other sites (metastatic/secondary bone cancer). Metastatic bone cancer is far more common than primary bone cancer.

Types of Primary Bone Cancer

  • Osteosarcoma
    • Most common primary malignant bone tumor (35%).
    • Peak age: Adolescents/young adults (10–30 yrs); second peak >60 yrs.
    • Locations: Metaphyses of long bones (knee, shoulder, hip).
    • Subtypes: Conventional (high-grade), telangiectatic, parosteal (low-grade).
  • Chondrosarcoma
    • 2nd most common (25–30%); arises from cartilage.
    • Peak age: Adults >40 yrs.
    • Locations: Pelvis, femur, humerus, ribs.
    • Grades I–III: Low-grade (slow-growing) vs. high-grade (aggressive).
  • Ewing Sarcoma
    • 10–15% of primary bone cancers.
    • Peak age: Children/teens (5–20 yrs).
    • Locations: Diaphyses of long bones, pelvis, ribs.
    • Key feature: *Chromosomal translocation **t(*11;22).
  • Rare Types
    • Chordoma: Spine/skull base (notochord remnant).
    • Giant Cell Tumor of Bone: Locally aggressive (may metastasize).
    • Malignant Fibrous Histiocytoma (MFH)/Undifferentiated Pleomorphic Sarcoma (UPS).

Metastatic Bone Cancer

  • 20–50× more common than primary bone cancer.
  • Common primaries: Breast, prostate, lung, kidney, thyroid.
  • Presentation: Bone pain, fractures, hypercalcemia.

Common Symptoms:

  • Persistent bone pain (worsens at night or with activity).
  • Swelling/tenderness near a joint.
  • Pathological fracture (bone breaks from minor injury).
  • Systemic: Weight loss, fatigue (advanced disease).
    🔴 Red Flag: Unexplained bone pain lasting >2–3 weeks warrants imaging.

Risk Factors

  • Genetic Syndromes:
    • Li-Fraumeni (TP53), Hereditary RB (RB1), Paget’s disease of bone.
  • Radiation Exposure: Prior therapeutic radiation.
  • Bone Marrow Transplant: ↑ Risk of osteosarcoma.
  • Age: Osteosarcoma/Ewing (teens/young adults); chondrosarcoma (older adults).

Diagnosis

  • Imaging:
    • X-ray: Initial study (shows "moth-eaten" bone destruction, periosteal reaction).
    • MRI: Defines tumor extent in bone/soft tissue.
    • CT/PET-CT: Staging (chest CT for lung mets; PET for systemic spread).
    • Bone Scan: Detects multifocal disease.
  • Biopsy:
    • Critical for diagnosis. Done by an interventional radiologist or orthopedic oncologist to avoid contamination.
  • Lab Tests:
    • Alkaline phosphatase (↑ in osteosarcoma), LDH (prognostic in Ewing).

Treatment Options:

1. Surgery:

  • Limb-sparing resection: Remove tumor + margin of healthy tissue; reconstruct with prosthesis/graft.
  • Amputation: Needed if the tumor involves nerves/vessels.

2. Chemotherapy:

  • Osteosarcoma/Ewing: Neoadjuvant (pre-surgery) + adjuvant (post-surgery).
    • Regimens: MAP (methotrexate/doxorubicin/cisplatin) for osteosarcoma; VDC/IE (vincristine/doxorubicin/cyclophosphamide + ifosfamide/etoposide) for Ewing.
  • Chondrosarcoma: Chemoresistant (used only in advanced dedifferentiated types).

3. Radiation Therapy:

  • Ewing sarcoma: Radiosensitive; used for unresectable sites (pelvis/spine).
  • Chordoma: Proton beam therapy (skull base/sacrum).

4. Targeted Therapies & Immunotherapy:

  • Denosumab (for giant cell tumor).
  • Clinical trials: TKIs, mTOR inhibitors, checkpoint inhibitors.

Prognosis

Tumor Type 5-Year Survival Key Prognostic Factors
Localized Osteosarcoma 60–75% Good response to chemo, limb location
Metastatic Osteosarcoma <30% Lung mets, poor chemo response
Chondrosarcoma (Low-Grade) >90% Grade, resectability
Chondrosarcoma (High-Grade) 30–50%
Localized Ewing Sarcoma 70–80% Pelvic site, large size, chemo response

Frequently Asked Questions (FAQ)

Q1: What is the difference between primary and metastatic bone cancer?
Primary bone cancer originates in bone tissue itself (e.g., osteosarcoma, chondrosarcoma, Ewing sarcoma). Metastatic bone cancer originates in another organ (such as the breast, prostate, or lung) and spreads to the bone. Metastatic bone cancer is 20–50 times more common than primary bone cancer.

Q2: Who is most commonly affected by osteosarcoma?
Osteosarcoma is most common in adolescents and young adults (ages 10–30), typically near the knee, shoulder, or hip. It accounts for about 35% of primary bone cancers. There is a second, smaller peak of incidence in adults over 60 years old.

Q3: What are the warning signs of bone cancer?
The most common symptoms are persistent bone pain (especially at night or during activity), swelling or tenderness near a joint, and sometimes a pathological fracture — a bone break caused by minor trauma. Unexplained bone pain lasting more than 2–3 weeks should be evaluated with imaging.

Q4: How is primary bone cancer treated?
Treatment depends on the type. Osteosarcoma and Ewing sarcoma are typically treated with a combination of chemotherapy and surgery (limb-sparing resection or, rarely, amputation). Chondrosarcoma is largely chemotherapy-resistant and is primarily treated with surgery. Radiation therapy is used for Ewing sarcoma and certain other types.

Q5: Can a limb be saved during bone cancer surgery?
In most cases, yes. Modern limb-sparing surgery removes the tumor along with a margin of healthy tissue and reconstructs the area using a prosthetic implant or bone graft. Amputation is reserved for cases where nerves or blood vessels are too involved to allow safe removal otherwise.

Q6: What are the survival rates for bone cancer?
Survival varies greatly by type and stage. Localized osteosarcoma has a 5-year survival rate of 60–75%; localized Ewing sarcoma around 70–80%. Low-grade chondrosarcoma carries a 5-year survival exceeding 90%. Metastatic disease has a significantly worse prognosis across all types.

Q7: Are there genetic risks associated with bone cancer?
Certain inherited conditions increase risk, including Li-Fraumeni syndrome (TP53 mutation), hereditary retinoblastoma (RB1 mutation), and Paget's disease of bone. Previous radiation exposure to bone is also a known risk factor for secondary osteosarcoma.

Medical Disclaimer

MediPulse publishes this content for patient education. It may not reflect the latest guideline changes in every jurisdiction. Do not delay seeking care because of something you read here.